NCT04566393 2026-01-28Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesxCuresAvailable
NCT05974410 2025-10-02Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsAVM Biotechnology IncAvailable
NCT04681248 2025-08-03Expanded Access Use of DKN-01 for the Treatment of Advanced Solid TumorsLeap Therapeutics, Inc.No longer available
NCT03842865 2025-06-05Expanded Access of Vigil in Solid TumorsGradalis, Inc.Temporarily not available
NCT06751524 2024-12-30Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc.Available
NCT03554434 2020-03-02An Expanded Access Program for AM0010 (Pegilodecakin)Eli Lilly and CompanyNo longer available
NCT03079687 2017-10-25Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.AstraZenecaApproved for marketing
NCT03025867 2017-04-17Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian CancerTesaro, Inc.Approved for marketing